The semaglutide peptide sequence and what it tells us about how Wegovy works

Why the sequence was redesigned from GLP-1 in the first place

The body's native GLP-1 peptide is broken down by an enzyme called DPP-4 within two minutes of being released from gut cells. That speed makes it useless as a medicine in its natural form. Chemists at Novo Nordisk solved this by altering one amino acid (substituting the residue at position 8) so DPP-4 can no longer cleave the chain. A second modification attaches a C18 fatty-acid tail to the amino acid at position 26. This tail binds reversibly to albumin, a protein that circulates in the bloodstream, and the albumin acts as a reservoir, releasing semaglutide slowly over days rather than minutes.

The practical result is a molecule that activates GLP-1 receptors in the brain, gut and pancreas for a full seven days from a single injection. Those receptors signal reduced appetite, slower gastric emptying and, in people with type 2 diabetes, improved insulin release. For weight management, the appetite signal is the clinically significant one. If you want to go deeper on the structural chemistry, the amino-acid sequence breakdown covers each modification in more detail.

The semaglutide sequence is the same whether the medicine is delivered by injection or tablet. Oral delivery adds a further challenge: stomach acid and digestive enzymes would ordinarily destroy a peptide this size before it reaches the bloodstream. The Wegovy tablet addresses this with an absorption enhancer called SNAC, which transiently raises local pH and forms a protective environment around the peptide at the gut wall. The underlying semaglutide molecule is chemically identical either way.

What the sequence's receptor selectivity means for the results evidence

GLP-1 receptor agonists as a class work through a single receptor. That selectivity shapes both the benefit profile and the side-effect profile in predictable ways, because researchers know exactly which tissues are being targeted. The STEP 1 trial used this understanding to design its endpoints: the primary outcome was percentage body-weight change, and the mechanism behind that change (reduced caloric intake driven by hypothalamic GLP-1 receptor activation) was consistent with the peptide's known pharmacology.

Average weight loss of around 15% at the 2.4 mg maintenance dose in STEP 1 represented a step change in what an injectable peptide medicine could achieve at the time. NICE subsequently recommended semaglutide for weight management under specific conditions, as set out in NICE technology appraisal TA875. The NHS recommends it within specialist weight management services, for a maximum of two years, with multidisciplinary support — the sequence itself is just one part of a wider clinical picture. You can read more about the licensed uses and eligibility criteria for Wegovy on a separate page.

Understanding the receptor selectivity also helps explain the gastrointestinal side-effect pattern. Nausea, vomiting, loose stools and constipation are among the most commonly reported effects, particularly when starting or after a dose increase. These occur because GLP-1 receptors line the gut as well as the brain, and the peptide slows gastric emptying throughout. For most people they are mild to moderate and ease within days to a couple of weeks.

How the peptide sequence compares with tirzepatide's dual-receptor approach

Tirzepatide, marketed in the UK as Mounjaro, is a different peptide that activates both the GLP-1 and GIP receptors. Its sequence is engineered to fit two receptor shapes rather than one, which is why it is described as a dual agonist. In the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks in adults with obesity and no diabetes.

That result reflects differences in receptor pharmacology, not simply in dose or formulation. Whether the extra receptor pathway matters for a specific person depends on their clinical picture, not on the peptide sequence alone. A prescriber considers factors including existing conditions, contraindications, medicines interactions and individual tolerability before recommending one approach over the other. The weight-loss treatment overview compares both options in accessible terms.

For people specifically interested in the structural differences between the two peptides, our page on how semaglutide peptide is categorised, synthesised and distinguished from related molecules covers this class in detail. The short practical check worth doing: if you are considering any online pharmacy for a peptide medicine like Wegovy, you can verify it holds a valid GPhC registration at pharmacyregulation.org/registers in under a minute. Genuine pharmacies are listed there; those that are not should be avoided.

If you'd like to understand the full cost picture before going any further, the Wegovy price comparison page sets out what a private prescription typically includes and what headline prices often leave out. When you are ready to talk through whether Wegovy is clinically appropriate for you, start your free consultation with our prescribers.